T. Rowe Price Associates
ELDN icon

T. Rowe Price Associates’s Eledon Pharmaceuticals ELDN Stock Holding History

T. Rowe Price Associates’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Buy
63,984
+13,822
+28% +$50.3K ﹤0.01% 2916
2026
Q1 		$155K Buy
50,162
+20,663
+70% +$48.7K ﹤0.01% 2906
2025
Q4 		$45K Hold
29,499
– – ﹤0.01% 3040
2025
Q3 		$77K Hold
29,499
– – ﹤0.01% 2968
2025
Q2 		$80K Buy
+29,499
New +$88.5K ﹤0.01% 2932

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates's ELDN Position: Q2 2026 in Review

T. Rowe Price Associates increased its Eledon Pharmaceuticals (ELDN) stake by 28% in Q2 2026, buying an estimated $50.3K and bringing the position to 63,984 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #2916.

T. Rowe Price Associates first reported a position in ELDN in Q2 2025 and has held it in 5 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • T. Rowe Price Associates held 63,984 shares of Eledon Pharmaceuticals worth $253K as of Q2 2026.
  • T. Rowe Price Associates bought 13,822 Eledon Pharmaceuticals shares in Q2 2026, an estimated $50.3K.
  • Eledon Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2916 holding.
  • T. Rowe Price Associates first reported a position in Eledon Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.